The Growing Role of Partnerships in Modern Bioprocessing and Biopharma R&D

Discover how strategic partnerships are transforming bioprocessing and biopharma drug development, from early process design to scalable biologics manufacturing. Learn actionable insights on accelerating timelines, reducing risk, and improving supply readiness across complex biologic pipelines.

Register Free: https://www.biopharminternational.com/bp_w/bioprocessing

Event Overview:

In the debut episode of BioPharm Drug Digest, we unpack how strategic, end-to-end partnerships in bioprocessing and biopharma development are reshaping biologics, process development, and manufacturing workflows. Industry alliances are compressing timelines, reducing risk from discovery through scalable supply, and driving innovation in complex molecule production, reinforcing their pivotal role in accelerating biotherapeutic delivery worldwide.

Key Learning Objectives:

• Partnership integration across process development and bioprocessing
• Impact of collaboration on timelines, risk, and manufacturability
• Early development–manufacturing alignment for scalable biologics
• Evolving partnership models supporting complex biologic pipelines

Who Should Attend:

• Bioprocessing and process development scientists
• Biopharma R&D leaders
• Manufacturing and operations professionals
• Program and project managers
• Strategy and alliance professionals

Speakers:

Manisha P. Desai, PhD
Senior Vice President, Product Development, Global Product & Supply
Bristol Myers Squibb

Dr. Desai is a seasoned pharmaceutical executive and strategic leader who, throughout her more-than-25-year career at Bristol Myers Squibb (BMS), has developed extensive expertise in the biopharma industry, with a focus on end-to-end chemistry, manufacturing, and controls development. This includes the design and development, scale-up, and technology transfer for both oral and parenteral drug products for BMS’s small and large molecule portfolio, as well as combination products, to manufacturing sites. In addition to her technical expertise, Dr. Desai has excelled in developing and executing organizational strategy, leading strategic partnerships, building high-performing teams, managing large global organizations, shaping organizational culture, and guiding teams through change.

J.D. Mowery
Division President, CDMO Business
Bora Pharmaceuticals

Mowery brings nearly 25 years of leadership experience in the contract development and manufacturing organization (CDMO) and biopharmaceutical industries, with a strong track record of driving innovation, growth, and operational excellence. Before joining Bora, he served as CEO of KBI Biopharma and Selexis SA, where he successfully led global CDMO operations across multiple continents. His expertise spans end-to-end pharmaceutical operations, including manufacturing, tech transfer, facility construction, business development, and sales and marketing. Throughout his career, Mowery has contributed to the success of some of the industry’s most respected companies, including Genentech, Celgene, Juno Therapeutics, Treadwell Therapeutics, and leading CDMOs such as Lonza and AGC Biologics.

Register Free: https://www.biopharminternational.com/bp_w/bioprocessing